Share on StockTwits

Shares of United Therapeutics (NASDAQ:UTHR) have earned an average recommendation of “Buy” from the fifteen brokerages that are covering the company, AmericanBankingNews.com reports. Five analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $102.21.

UTHR has been the subject of a number of recent research reports. Analysts at Wedbush raised their price target on shares of United Therapeutics from $119.00 to $133.00 in a research note on Thursday, July 31st. Separately, analysts at RBC Capital raised their price target on shares of United Therapeutics from $90.00 to $93.00 in a research note on Thursday, July 31st. Finally, analysts at HC Wainwright raised their price target on shares of United Therapeutics from $120.00 to $150.00 in a research note on Wednesday, July 30th. They now have a “buy” rating on the stock.

In other United Therapeutics news, CEO Martine A. Rothblatt unloaded 4,115 shares of the stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $88.40, for a total value of $363,766.00. The sale was disclosed in a document filed with the SEC, which is available at this link.

Shares of United Therapeutics (NASDAQ:UTHR) traded up 0.50% during mid-day trading on Tuesday, hitting $87.84. The stock had a trading volume of 15,158 shares. United Therapeutics has a 52-week low of $70.34 and a 52-week high of $116.65. The stock has a 50-day moving average of $90.82 and a 200-day moving average of $96.35. The company has a market cap of $4.152 billion and a price-to-earnings ratio of 16.89.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $2.57 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.75 by $0.82. The company had revenue of $322.80 million for the quarter, compared to the consensus estimate of $308.04 million. During the same quarter last year, the company posted $1.52 earnings per share. United Therapeutics’s revenue was up 15.0% compared to the same quarter last year. On average, analysts predict that United Therapeutics will post $8.55 earnings per share for the current fiscal year.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.